Kite’s Yescarta Is First CAR-T To Move Into Second-Line Lymphoma

 
• By Joseph Haas
  
Cancer cell therapy
Kite obtains first second-line cancer indication for a CAR-T therapeutic • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip